An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
CheckMate 057: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 057
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Capital Federal, Buenos Aires 1426, Argentina
Capital Federal, Buenos Aires 1431, Argentina
Ciudad de Buenos Aires, Buenos Aires C1181ACH, Argentina
Vizcaya, 48903, Spain